Meta description: Glenmark Pharmaceuticals Europe Limited recalls Fingolimod Glenmark 0.5 mg Hard Capsules due to stability testing issues. Published on 2026-01-21T22:00:33.000Z.
Glenmark Pharmaceuticals Europe Limited has initiated a precautionary recall of one batch of Fingolimod Glenmark 0.5 mg Hard Capsules. This decision follows stability testing that showed out-of-specification results, indicating a potential delay in the product’s efficacy. As a result, the company is taking proactive measures to ensure patient safety.
Navigation: What changed? | Who is affected? | FAQ | Conclusion | Disclaimer | Announcement Line
What changed?
The recall is a direct response to the stability testing results, which revealed a delay in the product’s efficacy. Glenmark Pharmaceuticals Europe Limited is committed to upholding the highest standards of quality and safety. In light of these findings, the company has chosen to recall the affected batch as a precautionary measure.
Stability Testing Results
The stability testing conducted on the Fingolimod Glenmark 0.5 mg Hard Capsules revealed out-of-specification results. These results indicate a potential delay in the product’s efficacy, which could impact patient treatment outcomes. The company’s primary concern is patient safety, and this recall is a proactive step to mitigate any potential risks.
Who is affected?
The recall affects one batch of Fingolimod Glenmark 0.5 mg Hard Capsules. Patients who have been prescribed this medication should consult their healthcare provider for guidance on alternative treatment options. Healthcare professionals are advised to inspect their inventory and quarantine the affected batch to prevent further distribution.
Next Steps
Patients and healthcare professionals can find more information on the recall by visiting the official website of Glenmark Pharmaceuticals Europe Limited or contacting their local regulatory authority. The company will provide updates on the recall and any subsequent actions that may be necessary.
FAQ
- What is the reason for the recall? The recall is due to stability testing results that showed out-of-specification results, indicating a potential delay in the product’s efficacy.
- Which batch is affected? The affected batch is being recalled as a precautionary measure.
- What should patients do? Patients should consult their healthcare provider for guidance on alternative treatment options.
Conclusion
In conclusion, Glenmark Pharmaceuticals Europe Limited has initiated a precautionary recall of one batch of Fingolimod Glenmark 0.5 mg Hard Capsules due to stability testing issues. The company’s primary concern is patient safety, and this recall is a proactive step to mitigate any potential risks. Patients and healthcare professionals are advised to take necessary precautions and follow the guidance provided by the company and regulatory authorities.
Disclaimer
This information is not intended to be taken as legal advice. It is the responsibility of healthcare professionals to consult the official website of Glenmark Pharmaceuticals Europe Limited and relevant regulatory authorities for the most up-to-date information on the recall.
Announcement Line
For full information about the announcement, see the link below.
https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-glenmark-pharmaceuticals-europe-limited-fingolimod-glenmark-0-dot-5-mg-hard-capsules-el-26-a-slash-02